Oteseconazole (VT-1161): Selective Tetrazole CYP51 Inhibi...
Oteseconazole (VT-1161): Selective Tetrazole CYP51 Inhibitor for Candida Infections
Executive Summary: Oteseconazole (VT-1161) is a tetrazole-class lanosterol 14α-demethylase (CYP51) inhibitor developed specifically for the targeted management of Candida infections, including those resistant to fluconazole. It demonstrates low minimum inhibitory concentrations (MICs) against Candida albicans, Candida glabrata, and related species, while sparing human CYP450 enzymes, thus minimizing drug-drug interaction risk. APExBIO provides Oteseconazole (SKU: BA1665) in a research-grade format, with validated selectivity and stability data (see Oteseconazole (VT-1161)). Recent peer-reviewed studies confirm its clinical and laboratory relevance (Luo et al., 2025, DOI). The compound is not active against Aspergillus fumigatus and is intended for prompt use in solution due to stability considerations.
Biological Rationale
Invasive fungal infections (IFIs) are associated with significant morbidity and mortality, with over 1.5 million deaths annually worldwide (Luo et al., 2025). Candida species, including C. albicans, C. glabrata, C. tropicalis, and C. parapsilosis, are among the leading causes of IFIs and are prioritized on the WHO Fungal Priority Pathogens List (FPPL) (DOI). Traditional azole antifungals inhibit fungal CYP51, disrupting ergosterol biosynthesis and compromising cell membrane integrity. However, first- and second-generation azoles (imidazoles and triazoles) often interact with human CYP enzymes, leading to adverse drug-drug interactions. The emergence of fluconazole-resistant Candida strains necessitates the development of more selective and potent antifungal agents (related article). Oteseconazole represents a next-generation tetrazole CYP51 inhibitor designed to address these limitations by combining high fungal selectivity with robust antifungal activity and improved safety profiles.
Mechanism of Action of Oteseconazole (VT-1161)
Oteseconazole (CAS No. 1340593-59-0) is a highly selective inhibitor of fungal lanosterol 14α-demethylase (CYP51), a key enzyme in ergosterol biosynthesis. Ergosterol is essential for maintaining fungal cell membrane integrity and function. By binding to the heme group of fungal CYP51, Oteseconazole blocks the demethylation of lanosterol, leading to ergosterol depletion and accumulation of toxic sterol intermediates. This disruption of membrane structure inhibits fungal growth and viability (Luo et al., 2025). Notably, Oteseconazole's tetrazole group confers high specificity for fungal CYP51 over human CYP isoforms, reducing off-target metabolic inhibition. The IC50 for human CYP3A4 is 65 μM, which is substantially higher than that of triazole or imidazole antifungals, providing a favorable safety margin (APExBIO).
Evidence & Benchmarks
- Oteseconazole demonstrates MIC values of ≤0.00625 to 0.1 μg/mL against C. albicans, C. tropicalis, C. parapsilosis, C. glabrata, C. krusei, and Cryptococcus neoformans in standardized in vitro assays (Luo et al., 2025).
- It remains active against fluconazole-resistant Candida strains, showing consistent MICs within the same range (DOI).
- No inhibitory activity is observed against Aspergillus fumigatus at concentrations up to 64 μg/mL, establishing its Candida-centric spectrum (DOI).
- The compound's IC50 for human CYP3A4 is 65 μM, significantly higher than its antifungal activity range, resulting in a reduced drug-drug interaction profile (APExBIO).
- Oteseconazole exhibits oral bioavailability suitable for maintaining plasma concentrations above MIC values, supporting its use in recurrent vulvovaginal candidiasis (RVVC) prophylaxis (Carmofur.com).
- In vivo studies confirm the efficacy of the tetrazole scaffold in reducing toxicity and improving selectivity compared to triazole and imidazole analogs (Luo et al., 2025).
Applications, Limits & Misconceptions
Oteseconazole (VT-1161) is primarily used for the laboratory and clinical management of Candida infections, including those resistant to standard azole antifungals. It is especially indicated for the prevention of recurrent vulvovaginal candidiasis (RVVC), where it sustains plasma levels above the MIC for relevant pathogens (product page). The high selectivity for fungal CYP51 makes it suitable for use in polypharmacy contexts due to its low likelihood of CYP-mediated drug-drug interactions. The product is supplied by APExBIO as a solid (molecular weight 527.39, formula C23H16F7N5O2) and should be stored at -20°C. Solutions should be prepared fresh and used promptly, as they are not intended for long-term storage.
Several related articles delve into Oteseconazole's mechanism and workflow integration. For example, this article provides a mechanistic overview, while the current dossier adds updated clinical benchmarks and selectivity data. Another resource examines its application boundaries, whereas this article details explicit MIC data and addresses practical storage constraints. For scenario-driven laboratory guidance, see this article; the present review extends by clarifying selectivity and preparation caveats.
Common Pitfalls or Misconceptions
- Not effective against Aspergillus species: Oteseconazole shows no activity against Aspergillus fumigatus (MIC >64 μg/mL).
- Solutions are unstable long-term: Prepared solutions should not be stored; use immediately for reproducible results.
- Not a pan-fungal agent: Its primary activity is against Candida and Cryptococcus; it is not indicated for molds.
- Does not inhibit all human CYPs: While highly selective, minor off-target effects may occur above therapeutic concentrations.
- Not suitable for topical formulations unless validated: Current clinical use is oral; topical protocols require additional validation.
Workflow Integration & Parameters
For in vitro antifungal assays, Oteseconazole is typically tested in gradient concentrations of 0.00625–0.1 μg/mL against Candida spp. Use sterile, buffered media (e.g., RPMI 1640, pH 7.0), and incubate at 35°C for 24–48 hours. Include resistant and wild-type control strains for benchmarking. For cell viability or mechanistic studies, Oteseconazole can be dissolved in DMSO (≤0.1% final concentration). Store powder at -20°C and avoid repeated freeze-thaw cycles. For clinical and translational research, maintain dosing schedules that sustain plasma concentrations above established MICs for target pathogens. Refer to the BA1665 kit documentation for detailed preparation protocols and troubleshooting tips.
Conclusion & Outlook
Oteseconazole (VT-1161) represents a significant advance in antifungal therapy, offering potent and selective inhibition of fungal CYP51 with reduced risk of drug-drug interactions. Its utility against fluconazole-resistant Candida species makes it a valuable tool for both laboratory and clinical research. Ongoing studies are expected to further elucidate its pharmacodynamics and extend its utility to additional challenging mycoses. APExBIO continues to provide high-quality, well-characterized Oteseconazole (BA1665) for academic and translational research.